Lantheus has agreed to make an initial strategic equity investment of A$7.5 million in RadiopharmOffer price for the shares of A$0.05 represents a 47% premium to the last closing price of $0.034 on 19...
SYDNEY, Australia, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic...
SYDNEY, Australia, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, œRadiopharm or the œCompany), a developer of radiopharmaceutical products for both diagnostic and therapeutic...
Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer
Radiopharm Theranostics Enters Into Supply Agreement with TerThera for Terbium-161 Isotope
Radiopharm Theranostics Invited to Participate in Jefferies Radiopharma Innovation Summit
Dr Ken Herrmann Appointed to RAD Scientific Advisory Board
Radiopharm Theranostics Partners With Next Generation Preclinical Platform for Therapeutic Radiopharmaceuticals
Radiopharm Theranostics Initiates Process for Nasdaq Listing
Radiopharm Theranostics, a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, and NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, announced they have entered into a clinical supply agreement that will see NorthStar supply Radiopharm with Actinium-225.